List of Excipients in Branded Drug OMEPRAZOLE/BICARBONATE

« Back to Dashboard

Generic Drugs Containing OMEPRAZOLE/BICARBONATE

Company	Ingredient	NDC	Excipient
AvKARE	omeprazole and sodium bicarbonate	42291-585	ALCOHOL
AvKARE	omeprazole and sodium bicarbonate	42291-585	AMMONIA
AvKARE	omeprazole and sodium bicarbonate	42291-585	BUTYL ALCOHOL

What are the Most Frequently-Used Excipients in OMEPRAZOLE/BICARBONATE?

# Of NDCs	Excipient
3	ALCOHOL
3	AMMONIA
3	BUTYL ALCOHOL

Omeprazole/Bicarbonate Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Omeprazole/bicarbonate products use sodium bicarbonate as both an alkalizing excipient and a functional stabilizer. The formulation creates an alkaline microenvironment that limits acid degradation of omeprazole before absorption. This approach supports immediate-release capsules, oral suspensions, and lower-dose over-the-counter products.

The main commercial opportunity is no longer basic generic substitution. U.S. composition patents covering the original omeprazole/sodium bicarbonate platform have largely expired, shifting competition toward dosage-form convenience, sodium reduction, pediatric delivery, adherence, manufacturing efficiency, and differentiated acid-suppression claims. The principal risks are high sodium loading, moisture sensitivity, dose uniformity, intellectual-property crowding, and limited room for premium pricing.

What is the omeprazole/bicarbonate formulation strategy?

Omeprazole is a proton-pump inhibitor that is unstable in acidic conditions. Conventional delayed-release omeprazole products protect the drug with enteric-coated granules or tablets. Omeprazole/bicarbonate products use a different strategy: sodium bicarbonate raises gastric pH rapidly and protects omeprazole during gastric transit.

The commercial reference product is Zegerid, marketed in prescription and over-the-counter forms. The prescription product contains omeprazole and sodium bicarbonate in immediate-release capsules or powder for oral suspension. The OTC product is generally a 20-mg omeprazole/1,100-mg sodium bicarbonate product used for frequent heartburn treatment.

Attribute	Omeprazole/bicarbonate approach
Active ingredient	Omeprazole
Functional excipient	Sodium bicarbonate
Release design	Immediate release
Protection mechanism	Local and systemic alkalinization
Typical strengths	20 mg and 40 mg prescription; 20 mg OTC
Main dosage forms	Capsule, powder for oral suspension, oral powder
Key formulation issue	Maintaining omeprazole stability in an alkaline, moisture-controlled system
Main commercial advantage	Rapid availability without an enteric-coated dosage form
Main commercial limitation	High sodium burden and relatively large excipient mass

FDA labeling identifies sodium bicarbonate as a component of the product's formulation and warns about sodium-related use restrictions, including patients requiring sodium restriction or those at risk from sodium load (U.S. Food and Drug Administration [FDA], 2023a).

How does sodium bicarbonate protect omeprazole?

Sodium bicarbonate performs several functions at once.

First, it neutralizes gastric acid. Second, it produces a transient alkaline environment around the omeprazole dose. Third, it helps reduce acid-mediated degradation before the drug reaches the small intestine. The mechanism differs from enteric protection, which delays drug release until the dosage form reaches a higher-pH intestinal environment.

The formulation therefore depends on more than the nominal omeprazole dose. Product performance is influenced by:

• Bicarbonate-to-omeprazole ratio
• Particle-size distribution
• Moisture content
• Granulation or blending uniformity
• Dissolution rate
• Packaging protection
• Exposure to heat and humidity
• The patient's gastric acid environment

A commercial developer cannot treat sodium bicarbonate as an inert filler. Changes in bicarbonate level, particle size, compression force, or dosage-form geometry can alter pH, dissolution, stability, and bioavailability.

What excipients are used with omeprazole and bicarbonate?

The excipient system normally includes sodium bicarbonate plus processing and dosage-form excipients. Exact composition varies by manufacturer and dosage form.

Capsule formulations

Capsules may contain:

• Sodium bicarbonate as the principal alkalizing excipient
• Fillers or bulking agents
• Lubricants and flow aids
• Capsule-shell materials
• Moisture-control components
• Colorants, where permitted

The principal development challenge is achieving uniform distribution of a relatively low omeprazole quantity within a larger bicarbonate mass. Segregation during filling can create content-uniformity failures.

Capsule systems also require moisture protection. Omeprazole degradation and bicarbonate behavior can change when water enters the formulation. High-barrier blister packaging, desiccants, and low-moisture manufacturing controls can become important commercial differentiators.

Powder-for-suspension formulations

Powder products permit reconstitution before administration and can support patients who have difficulty swallowing capsules. They may use:

• Sodium bicarbonate
• Suspending agents
• Sweeteners
• Flavors
• Wetting agents
• Preservatives, depending on the product and in-use period
• Viscosity modifiers

The formulation must maintain dose uniformity after reconstitution. Settling, caking, incomplete redispersion, and short in-use stability can reduce patient compliance and create regulatory risk.

Orally dispersible and pediatric products

Pediatric or geriatric products may use lower-volume powders, orally dispersible granules, or liquid systems. Commercial developers must balance palatability against the alkaline and saline taste of sodium bicarbonate. Taste masking is difficult because the bicarbonate load is pharmacologically functional and cannot simply be removed.

Potential approaches include:

• Microencapsulation of omeprazole particles
• Taste-masking polymers
• Flavored powder systems
• Unit-dose sachets
• Low-volume reconstitution
• Ready-to-use suspensions
• Device-assisted dosing

Any taste-masking layer must not prevent rapid bicarbonate contact with gastric contents or create a delayed-release profile inconsistent with the product's intended mechanism.

What formulations are protected by omeprazole/bicarbonate patents?

The historical patent estate focused on pharmaceutical compositions combining omeprazole with an alkaline compound, particularly bicarbonate, rather than on sodium bicarbonate as a conventional filler.

Relevant U.S. patent families include patents associated with immediate-release omeprazole/bicarbonate compositions and methods of reducing acid degradation. The foundational U.S. patents associated with the Zegerid platform include U.S. Patent No. 5,840,737 and related continuation or improvement filings. The principal commercial patent term for these early U.S. composition claims has expired.

Patent protection for a new product could still arise from narrower claims covering:

• A specific bicarbonate-to-omeprazole ratio
• A defined particle-size distribution
• Low-moisture granulation
• A particular powder-for-suspension system
• Taste-masked omeprazole particles
• A pediatric dose form
• A packaging configuration
• A specific dosing regimen
• Manufacturing controls that produce a defined stability profile

A developer should separate platform freedom to operate from product-specific patentability. Expiration of the original combination patent does not eliminate risk from later formulation, method-of-use, process, or packaging patents.

When did omeprazole/bicarbonate lose exclusivity?

Prescription Zegerid was approved in the United States in 2004. The original omeprazole/bicarbonate patent estate was subject to ordinary patent-term calculations, regulatory exclusivity, and any applicable patent-term adjustment. The earliest platform patents have expired, and multiple generic and authorized-generic products have entered the U.S. market.

Milestone	Commercial significance
1989	Prilosec omeprazole product approved in the United States
1990s	Omeprazole/bicarbonate composition patents filed and prosecuted
2004	Prescription Zegerid approved by FDA
2000s-2010s	Platform patent and regulatory exclusivity barriers declined
2010s onward	Generic omeprazole/bicarbonate products expanded
Current market	Competition centers on price, format, OTC positioning, and supply reliability

Exact Orange Book status must be assessed by product, NDA, patent listing, and current FDA publication. The Orange Book remains the controlling source for listed patents and regulatory exclusivity status, rather than historical product literature (FDA, 2024).

What is the FDA regulatory status of omeprazole/bicarbonate?

Omeprazole/bicarbonate products occupy two regulatory markets.

Prescription products are approved under an NDA or abbreviated pathway, depending on the product and reference-product relationship. OTC products are marketed under the FDA's nonprescription heartburn framework and must satisfy labeling, dose, duration, and safety requirements applicable to OTC acid reducers.

The regulatory profile is shaped by:

• Omeprazole identity and strength
• Sodium bicarbonate quantity
• Immediate-release performance
• Stability data
• Bioavailability or bioequivalence
• Labeling for sodium-sensitive populations
• Container-closure protection
• Dose uniformity
• Microbial quality for liquid products

A formulation that changes the bicarbonate level materially may require comparative clinical or pharmacokinetic support. A product cannot be treated as a simple strength change if the alteration changes gastric pH protection or omeprazole exposure.

How many patents cover omeprazole/bicarbonate products?

The answer depends on the product, jurisdiction, and claim type. The original U.S. platform was protected by a small group of composition and continuation patents, while later products may face a larger collection of formulation, process, packaging, and method-of-use filings.

For current freedom-to-operate analysis, relevant searches should cover:

1. Orange Book listings for prescription reference products.
2. FDA approval letters and product labels.
3. U.S. patents assigned to the original innovator and later manufacturers.
4. Patent families claiming omeprazole with alkaline stabilizers.
5. International applications in Europe, Canada, Japan, China, and major emerging markets.
6. Litigation and settlement records involving abbreviated applications.

The commercial relevance of a patent depends on claim scope, expiration, terminal disclaimers, maintenance status, prosecution history, and whether the claim reads on the proposed formulation. Patent counts alone do not measure estate strength.

How strong is the current patent estate?

The original platform estate is commercially weaker than it was during the launch period because the principal composition claims have aged out. The remaining patent opportunity is narrower and more technical.

Patent layer	Current strategic value
Broad omeprazole plus bicarbonate composition	Low where expired
Specific ratio or concentration	Moderate if technically supported
Pediatric or geriatric dosage form	Moderate to high
Taste-masked delivery	Moderate
High-stability packaging	Moderate, but often difficult to enforce broadly
Manufacturing process	Moderate if process is necessary for product performance
Method of use	Depends on indication and claim scope
Device or administration system	Potentially valuable for differentiated products

The strongest new filings will usually require comparative data showing an improvement in stability, bioavailability, administration, sodium exposure, palatability, or adherence. A claim based only on routine substitution of one filler or flavor for another is vulnerable to obviousness challenges.

What generic entry risks exist?

Generic entry risk is high for standard 20-mg and 40-mg immediate-release products because the therapeutic ingredient is established and the original platform has been commercialized for many years.

Key entry routes include:

• ANDA approval for a prescription reference product
• OTC monograph-based marketing where applicable
• Authorized-generic supply arrangements
• Regional products using similar omeprazole/bicarbonate compositions
• Contract-manufactured sachets, capsules, and powders

The remaining barriers are operational rather than fundamental:

• Stability under accelerated and long-term conditions
• Low-moisture processing
• Uniform filling
• Acceptable dissolution
• Sodium-labeling compliance
• Packaging validation
• Reliable API and excipient supply

Paragraph IV litigation risk is likely to be product-specific. If no unexpired Orange Book patent blocks the reference product, an ANDA applicant may face limited patent litigation exposure. If a later-listed formulation or method patent exists, the applicant may submit a Paragraph IV certification and trigger litigation under Hatch-Waxman procedures. FDA Orange Book records and the applicant's certification position control the timing analysis.

What commercial opportunities exist for excipient innovation?

The strongest commercial opportunities involve functional improvement, not commodity substitution.

Sodium-reduced formulations

Reducing sodium is strategically attractive but technically difficult. Sodium bicarbonate is central to the formulation, so a lower-sodium product may require another alkalizing system or a more efficient delivery design. Potential alternatives include carbonate or hydroxide systems, but each can affect tolerability, stability, dissolution, and regulatory comparability.

A successful sodium-reduced product could target patients with hypertension, heart failure, renal disease, or sodium-restricted diets. Such positioning would require careful clinical and labeling support.

Pediatric and geriatric delivery

Liquid and sachet products can address swallowing difficulties and improve dosing flexibility. Unit-dose packaging can reduce preparation errors. The commercial value is higher where the product provides a clear administration advantage over conventional delayed-release capsules.

Taste masking

Taste masking can support pediatric and OTC products. The most practical approaches are multiparticulates, flavored alkaline powders, coated drug particles, and low-volume suspensions. The key performance requirement is preservation of immediate availability and product stability.

Moisture-resistant packaging

Packaging is a meaningful development opportunity because moisture can affect both omeprazole stability and powder handling. High-barrier blisters, stick packs, desiccant-integrated bottles, and unit-dose sachets can support longer shelf life and better distribution in hot or humid markets.

Hospital and institutional use

Ready-to-administer powders or suspensions may support inpatient, long-term-care, and home-health settings. Institutional buyers value dose accuracy, preparation simplicity, reduced waste, and storage stability. These products may compete on total administration cost rather than retail price.

How does omeprazole/bicarbonate compare with conventional omeprazole?

Criterion	Omeprazole/bicarbonate	Conventional delayed-release omeprazole
Release mechanism	Immediate release with alkaline protection	Enteric protection
Main functional excipient	Sodium bicarbonate	Enteric polymers and coating excipients
Dosage-form complexity	Lower coating complexity, higher bicarbonate load	Higher coating and multiparticulate complexity
Sodium exposure	Material	Usually lower
Moisture sensitivity	Significant	Significant, especially for coated pellets
Pediatric flexibility	Strong for powders and suspensions	Often dependent on pellet administration
Manufacturing focus	Blend uniformity and alkalinity	Coating uniformity and acid resistance
Patent differentiation	Ratios, stability, delivery, process	Coating, pellet, release profile, formulation

The product choice depends on the target population. Omeprazole/bicarbonate is attractive where rapid administration, suspension delivery, or simplified immediate-release manufacturing matters. Conventional delayed-release omeprazole is often preferable where sodium exposure is a concern.

Which companies are challenging or competing with the reference product?

Competition includes the original Zegerid franchise, generic manufacturers, OTC private-label suppliers, and contract manufacturers. The competitive field is fragmented because the product is relatively mature and can be supplied through multiple channels.

The most commercially relevant competitors are likely to compete through:

• Retail price
• Private-label OTC distribution
• Unit-dose packaging
• Pediatric and institutional formats
• Supply continuity
• Sodium-labeling clarity
• Convenient administration

A definitive list of current ANDA applicants, active Paragraph IV certifications, settlements, and live Orange Book patents requires a product-date-specific FDA and court-record review. Historical patent expiration alone does not establish the current litigation position.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are concentrated in process control. The formulation must prevent segregation between a small active dose and a large sodium bicarbonate quantity. Low humidity, controlled particle size, validated blending, and high-barrier packaging are central controls.

Potentially protectable manufacturing features include:

• A defined dry-blending sequence
• Granulation under controlled moisture
• A particle-size relationship between omeprazole and bicarbonate
• A validated low-water-activity product
• A packaging system that preserves stability
• A reconstitution process with defined suspension performance

The strongest commercial strategy combines a narrow but defensible patent claim with a measurable product advantage. A generic capsule with no convenience or stability differentiation will face direct price competition.

What licensing opportunities exist?

Licensing opportunities are most plausible in three areas:

1. A validated low-sodium alkalizing system.
2. Pediatric or geriatric oral delivery technology.
3. Moisture-resistant packaging and unit-dose administration.

A licensee would likely seek freedom to operate across the active ingredient, excipient system, dosage form, manufacturing process, and target market. Royalty economics will be limited for undifferentiated generic products but may improve for branded OTC, pediatric, institutional, or specialty formulations.

Key Takeaways

• Sodium bicarbonate is a functional excipient that protects omeprazole through alkalinization; it is not a passive filler.
• The original broad U.S. omeprazole/bicarbonate platform patents have largely expired.
• Standard generic entry risk is high, while remaining patent value is concentrated in narrow formulation, process, packaging, and method claims.
• The most attractive excipient opportunities are sodium reduction, taste masking, pediatric delivery, moisture control, and unit-dose packaging.
• Sodium exposure is the principal clinical and commercial limitation.
• Manufacturing control must address blend uniformity, moisture sensitivity, dissolution, and stability.
• Premium pricing requires a measurable advantage over low-cost generic capsules and conventional delayed-release omeprazole.
• Current Orange Book listings, Paragraph IV certifications, settlements, and litigation must be assessed at the individual-product level.

FAQs

Can sodium bicarbonate be replaced in an omeprazole formulation?

Potentially, but replacement can change gastric pH, stability, dissolution, bioavailability, tolerability, and regulatory comparability. A substitute alkalizer would require formulation and clinical support.

Is omeprazole/bicarbonate suitable for patients on sodium-restricted diets?

The sodium content can be clinically relevant. Product labeling should be reviewed before use in patients with sodium restrictions, hypertension, heart failure, renal impairment, or other sodium-sensitive conditions.

Does an omeprazole/bicarbonate product need an enteric coating?

Not necessarily. The formulation uses alkalinization to protect omeprazole rather than relying exclusively on an enteric-coated dosage form.

Can an OTC omeprazole/bicarbonate product obtain new patent protection?

Yes, a later product may obtain patents for a novel dosage form, excipient ratio, taste-masking system, packaging configuration, manufacturing process, or method of use. The claims must satisfy novelty, nonobviousness, written-description, and enablement requirements.

What is the best commercial entry point for a new omeprazole/bicarbonate product?

A differentiated pediatric, geriatric, institutional, low-sodium, or unit-dose product is more commercially defensible than an undifferentiated standard capsule.

References

1. U.S. Food and Drug Administration. (2023a). Zegerid OTC: Omeprazole and sodium bicarbonate capsule, delayed release label. DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2004). Zegerid approval package and prescribing information. Center for Drug Evaluation and Research.

4. U.S. Patent No. 5,840,737. (1998). Pharmaceutical compositions containing omeprazole and bicarbonate. United States Patent and Trademark Office.

5. U.S. Food and Drug Administration. (2017). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (2023b). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.